StockTipsArenaBeta

BUY Mankind Pharma Limited — Anshul Jain, Lakshmishree Investment and Securities

BUYMankind Pharma Limited

byAnshul Jain, Lakshmishree Investment and SecuritiesHorizon: NA (inferred Swing (≤2wk))6 May 2026via Business Today

Entry₹2,320Stated
Target₹2,500
Total upside +7.76% (call closed)
Stop lossNot given
Exit—No position was opened
ExpiredNA
Follow Anshul Jain for new calls(32% target hit, 31 closed calls)Get alertsWatch MANKIND for new buy/sell callsGet alertsSee 1 active Swing call on MANKINDSee 258 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 9 Sept, 6:45 pm IST
2 supporting2 neutral0 opposing
Supports the BUY call (2)

1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·14 May · 5d ago

1 advisor has an active short-term BUY call on this stock, issued in the last 14 days

Advisor consensus · adjacent horizon·7 May · 2w ago

Neutral / worth noting (2)

Mankind Pharma Limited has received credit ratings from CARE Ratings Limited for its long-term/short-term bank facilities amounting to ₹1,000 crore. The ratings assigned are CARE AA+ (Stable) for long

NSE · Credit Rating- New·22 Apr · 4w ago

(opens in new tab)

Mankind Pharma Ltd has attached an intimation regarding credit ratings assigned by CARE Ratings Limited.

BSE · Company Update·22 Apr · 4w ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.